Recently, the final analysis of overall survival data of this trial showed that treatment with abemaciclib plus fulvestrant resulted in a statistically significant and clinically meaningful improvement of median overall survival of 9.4 months for patients with HR-positive, HER2-negative advanced breast cancer after prior endocrine therapy, regardless of menopausal status [363]. Here, ERBB2 is linked to breast carcinoma.